Industry News

Acute flaccid myelitis requires galvanized research response

  • Posted on: 4 April 2019
  • By: Shalini.Sharma

Acute flaccid myelitis (AFM) presents significant challenges not only to patients but also to researchers, and efforts must be accelerated to learn more about the condition, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, write in a new perspective published in mBio.

Indoco Remedies clears USFDA inspection

  • Posted on: 1 April 2019
  • By: PharmaTutor News

US Food and Drug Administration (USFDA), has cleared the sterile manufacturing facility of Indoco Remedies Limited, for Finished Dosages, located at Verna Industrial Area, Goa (Plant II). This inspection was carried out by USFDA in November 2018.


WHO urges governments to enforce bans on tobacco advertising, promotion and sponsorship, including in motor sport

  • Posted on: 16 March 2019
  • By: Shalini.Sharma

WHO is urging governments to enforce bans on tobacco advertising, promotion and sponsorship at sporting events, including when hosting or receiving broadcasts of Formula 1 and MotoGP events.

FDA takes steps to help reduce risks associated with surgical staplers and implantable staples

  • Posted on: 11 March 2019
  • By: Shalini.Sharma

U.S. Food and Drug Administration issued a Letter to Health Care Providers to alert them that the agency is aware of an increasing number of medical device reports associated with the use of surgical staplers for internal use and implantable surgical staples common devices used in many surgeries and to provide updated recommendations to help reduce risks associated with their use.

First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban

  • Posted on: 4 March 2019
  • By: Shalini.Sharma

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisationin the European Union for Ondexxya (andexanet alfa). This medicine is to be used as an antidote for adult patients taking the anticoagulant (clot-preventing) medicines apixaban or rivaroxaban, when reversal of their action is needed due to life-threatening or uncontrolled bleeding.

FDA, CDC, and CMS launch task force to help facilitate rapid availability of diagnostic tests during public health emergencies

  • Posted on: 1 March 2019
  • By: Shalini.Sharma

U.S. Food and Drug Administration, Centers for Disease Control and Prevention (CDC) and the Centers for Medicare and Medicaid Services (CMS) announced the launch of the Tri-Agency Task Force for Emergency Diagnostics. This task force has been created to help leverage the expertise of each agency to advance rapid development and deployment of diagnostic tests in clinical and public health laboratories during public health emergencies.

EU and Switzerland to improve information-sharing on good manufacturing practice through use of the EudraGMDP database

  • Posted on: 22 February 2019
  • By: Shalini.Sharma

The Swiss Agency for Therapeutic Products (Swissmedic) has started in 2019 to enter information on Good manufacturing practice (GMP) compliance as well as on manufacturing authorisations related to Swiss manufacturers into the European Union’s EudraGMDP database. This applies for all new or renewed manufacturing authorisations and the related GMP-certificates issued using new templates (similar to those of EMA). This will allow replacing the current practice of issuing paper documents, i.e. GMP certificates for certain regulatory procedures and therefore should lead to easier information-sharing and efficiency gains for all stakeholders.